Rosiglitazone Lowers Blood Pressure and Increases Arterial Compliance in Postmenopausal Women With Type 2 Diabetes
- Suzy Y. Honisett, PHD12,
- Lily Stojanovska, PHD1,
- Krishnankutty Sudhir, PHD2,
- Bronwyn A. Kingwell, PHD2,
- Tye Dawood, BSC2 and
- Paul A. Komesaroff, PHD2
- 1Department of Biomedical Sciences, Victoria University, Melbourne, Australia
- 2Baker Heart Research Institute, Melbourne, Australia
- Address correspondence to Assoc. Prof. Lily Stojanovska, Victoria University, Biomedical Sciences, Footscray Campus, PO Box 14428, MC, Melbourne, Australia 8008. E-mail: lily.stojanovska{at}vu.edu.au
Diabetes is associated with stiff large arteries, which plays an important role in the pathogenesis of vascular disease (1) and is the primary cause of mortality and morbidity with type 2 diabetes. Similarly, after menopause, women experience a dramatic increase in large artery stiffness and the rate of cardiovascular disease (2). Thiazolidinediones modulate glucose homeostasis (3) and exhibit a number of potential antiatherogenic actions (3), the collective effects of which remain to be fully elucidated in humans.
We therefore investigated whether rosiglitazone, the second member of the thaizolidinediones group, would improve blood pressure and arterial compliance, …
